Latest Breaking News On - Trial progress - Page 3 : comparemela.com

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesJill bertottiJason gardnerExchange commissionAmerican society of hematologyDrug administrationGood laboratory practiceAmerican societyNew orleansChief executive officerPotential significanceClinical developmentthePotential activeTransplant ineligible participants becameTrial progress

Magenta Therapeutics (MGTA) Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

Magenta Therapeutics (MGTA) Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJason gardnerAmerican society of hematologyGood laboratory practiceAmerican societyNew orleansChief executive officerPotential significanceClinical developmentthePotential activeTransplant ineligible participants becameTrial progressClinical development next stepsAutologous gene therapyasEnabling plansmagentaGood manufacturing practice

Magenta Therapeutics Presents Positive MGTA-117 Clinical

– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent.

United kingdomUnited statesJill bertottiJason gardnerExchange commissionAmerican society of hematologySignificance for clinical developmentDrug administrationGood laboratory practiceAmerican societyNew orleansChief executive officerPotential significancePotential activeTransplant ineligible participants becameTrial progress

Xilio Therapeutics (XLO) Reports Positive Prelim Phase 1 Dose-Escalation Data for XTX101

Xilio Therapeutics (XLO) Reports Positive Prelim Phase 1 Dose-Escalation Data for XTX101
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesStacey davisChris frankenfieldMartin huberRobert rossPaul clancyUli bialuchaJulissa vianaMelissa forstXilio therapeutics incDevelopment updatesDrug administrationResearch development rd expensesExchange commissionMerck co incCorporate communications

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022

– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through. | May 9, 2022

United statesUnited kingdomTheresa boniRob rossScott youngExchange commissionAmerican association for cancer researchAmerican society of clinicalSurface oncology incGlobenewswire incAnnual meetingSubsequent corporateOctagon capitalCancer researchTrial progressInvestigational new drug